Rhelion Life Sciences Corp.
RHEL
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.02M | 2.99M | 2.91M | 3.37M | 3.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.02M | 2.99M | 2.91M | 3.37M | 3.57M |
| Cost of Revenue | 1.88M | 1.95M | 1.83M | 2.12M | 2.19M |
| Gross Profit | 1.15M | 1.04M | 1.08M | 1.25M | 1.38M |
| SG&A Expenses | 4.33M | 4.17M | 4.06M | 4.16M | 4.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 0.00 | 0.00 | -119.70K | -119.70K |
| Total Operating Expenses | 6.22M | 6.13M | 5.90M | 6.17M | 6.60M |
| Operating Income | -3.19M | -3.14M | -2.98M | -2.80M | -3.03M |
| Income Before Tax | -5.17M | -3.85M | -3.47M | -3.02M | -3.16M |
| Income Tax Expenses | -234.50K | -123.40K | -117.70K | -96.00K | -75.20K |
| Earnings from Continuing Operations | -4.93 | -3.72 | -3.35 | -2.92 | -3.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 534.40K | 169.50K | 179.40K | 180.40K | 187.70K |
| Net Income | -4.40M | -3.55M | -3.17M | -2.74M | -2.89M |
| EBIT | -3.19M | -3.14M | -2.98M | -2.80M | -3.03M |
| EBITDA | -3.67M | -2.86M | -2.63M | -2.37M | -2.54M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.67B | 1.65B | 1.63B | 1.62B | 1.60B |
| Average Diluted Shares Outstanding | 1.67B | 1.65B | 1.63B | 1.62B | 1.60B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |